CHRONIC GRAFT VERSUS HOST DISEASE
Clinical trials for CHRONIC GRAFT VERSUS HOST DISEASE explained in plain language.
Never miss a new study
Get alerted when new CHRONIC GRAFT VERSUS HOST DISEASE trials appear
Sign up with your email to follow new studies for CHRONIC GRAFT VERSUS HOST DISEASE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for GVHD patients after multiple failed treatments
Disease control CompletedThis study tested a drug called axatilimab in 41 people with chronic graft-versus-host disease (cGVHD), a complication after a stem cell transplant where donor cells attack the body. Participants had already tried at least 2 other treatments. The goal was to find a safe dose and …
Matched conditions: CHRONIC GRAFT VERSUS HOST DISEASE
Phase: PHASE1, PHASE2 • Sponsor: Syndax Pharmaceuticals • Aim: Disease control
Last updated May 17, 2026 03:14 UTC
-
New combo therapy offers hope for tough transplant complication
Disease control CompletedThis study tested whether adding a low dose of Interleukin-2 (IL-2) to a standard therapy called Extra-Corporeal Photopheresis (ECP) could help people with chronic graft-versus-host disease (cGVHD) that did not respond to steroids. cGVHD is a serious condition where donor immune …
Matched conditions: CHRONIC GRAFT VERSUS HOST DISEASE
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated May 08, 2026 12:03 UTC
-
New hope for kids with chronic graft-versus-host disease: ibrutinib tested
Disease control CompletedThis study tested the drug ibrutinib in children with chronic graft-versus-host disease (cGVHD), a condition where donor immune cells attack the child's body after a stem cell transplant. The goal was to find the best dose and check safety. 59 children aged 1 to 22 took part. The…
Matched conditions: CHRONIC GRAFT VERSUS HOST DISEASE
Phase: PHASE1, PHASE2 • Sponsor: Pharmacyclics LLC. • Aim: Disease control
Last updated Apr 29, 2026 15:15 UTC